Loading clinical trials...
Loading clinical trials...
The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after li...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alnylam Pharmaceuticals
NCT06355934 · ATTR Amyloidosis
NCT06318260 · ATTR Amyloidosis Wild Type
NCT06367842 · ATTR Amyloidosis, Cardiopathy, and more
NCT06261216 · Amyloid Cardiomyopathy, Wild Type ATTR Amyloidosis
NCT06186167 · Amyloid, Cardiac Amyloidosis, and more
Clinical Trial SIte
Paris
Clinical Trial SIte
Münster
Clinical Trial SIte
Porto
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions